This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Classification of SIADH

Authoring team

SIADH can be divided according to the pattern of arginine vasopressin (AVP) secretion across a range of plasma osmolalities.

  • type A
    • commonest form of SIADH, is thought to be responsible for 60-70% of cases
    • characteristically seen in lung cancer and in nasopharyngeal tumors
    • patients are prone to develop severe hyponatraemia since plasma AVP concentrations are not suppressed physiologically by drinking
    • there is also a lower osmotic threshold for thirst appreciation

  • type B
    • common, seen in 20-40%
    • secretion of AVP occurs at lower plasma osmolalities than normal
    • since secretion of AVP is supressed at a lower osmotic threshold for AVP release, patients are protected against the progression to severe hyponatraemia

  • type C
    • rare
    • there is failure to suppress AVP at plasma osmolalties below the osmotic threshold, hence inappropriately high plasma AVP levels are seen even at low plasma osmolalities

  • type D
    • rare
    • low or undetectable AVP levels and no detectable abnormality in circulating AVP response o is thought to be due to nephrogenic SIADH (1)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.